Athira Other Liab vs Net Debt Analysis

ATHA Stock

USD 0.66 0.01 1.54%

Athira Pharma financial indicator trend analysis is way more than just evaluating Athira Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Athira Pharma is a good investment. Please check the relationship between Athira Pharma Other Liab and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

Other Liab vs Net Debt

Other Liab vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Athira Pharma Other Liab account and Net Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Athira Pharma's Other Liab and Net Debt is -0.82. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Net Debt in the same time period over historical financial statements of Athira Pharma, assuming nothing else is changed. The correlation between historical values of Athira Pharma's Other Liab and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Athira Pharma are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Other Liab i.e., Athira Pharma's Other Liab and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Other Liab

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Athira Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.As of December 1, 2024, Selling General Administrative is expected to decline to about 17.8 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	479K	845K	969K	631.1K
Cost Of Revenue	479K	1.0M	969K	899.2K

Reconciled Depreciation Cost Of Revenue

Athira Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Non Current Liabilities Other
Total Assets		0.78	0.6	0.63	1.0	0.77	0.97	-0.94	-0.59	0.63	0.95	0.88	0.45	0.48	0.79	0.99	0.95	0.84	1.0	-0.95	0.94	0.94	-0.41	1.0	0.99	0.69
Short Long Term Debt Total	0.78		0.72	0.75	0.76	0.88	0.78	-0.86	-0.72	0.56	0.86	0.51	0.58	-0.01	0.88	0.81	0.81	0.94	0.75	-0.78	0.75	0.84	0.07	0.76	0.81	0.87
Other Current Liab	0.6	0.72		1.0	0.57	0.72	0.69	-0.82	-1.0	0.27	0.76	0.17	0.97	-0.08	0.65	0.66	0.69	0.73	0.55	-0.79	0.73	0.79	0.37	0.57	0.66	0.83
Total Current Liabilities	0.63	0.75	1.0		0.61	0.74	0.72	-0.85	-1.0	0.33	0.79	0.22	0.96	-0.06	0.68	0.69	0.71	0.75	0.59	-0.82	0.76	0.82	0.35	0.61	0.69	0.84
Total Stockholder Equity	1.0	0.76	0.57	0.61		0.76	0.96	-0.92	-0.57	0.63	0.93	0.9	0.43	0.5	0.78	0.99	0.95	0.83	1.0	-0.94	0.93	0.93	-0.45	1.0	0.99	0.67
Other Liab	0.77	0.88	0.72	0.74	0.76		0.85	-0.82	-0.74	0.48	0.84	0.56	0.65	0.3	0.99	0.8	0.82	0.97	0.74	-0.83	0.86	0.87	0.03	0.76	0.8	0.79
Net Tangible Assets	0.97	0.78	0.69	0.72	0.96	0.85		-0.96	-0.7	0.55	0.97	0.8	0.57	0.44	0.85	0.98	0.98	0.87	0.96	-0.98	0.97	0.98	-0.27	0.96	0.98	0.78
Net Debt	-0.94	-0.86	-0.82	-0.85	-0.92	-0.82	-0.96		0.82	-0.52	-0.99	-0.66	-0.7	-0.21	-0.81	-0.96	-0.96	-0.87	-0.91	0.97	-0.93	-0.98	0.1	-0.92	-0.96	-0.87
Retained Earnings	-0.59	-0.72	-1.0	-1.0	-0.57	-0.74	-0.7	0.82		-0.26	-0.77	-0.17	-0.97	0.08	-0.67	-0.66	-0.7	-0.73	-0.55	0.79	-0.74	-0.8	-0.39	-0.57	-0.66	-0.84
Accounts Payable	0.63	0.56	0.27	0.33	0.63	0.48	0.55	-0.52	-0.26		0.57	0.68	0.12	0.33	0.54	0.61	0.44	0.56	0.63	-0.55	0.64	0.59	-0.18	0.63	0.62	0.38
Cash	0.95	0.86	0.76	0.79	0.93	0.84	0.97	-0.99	-0.77	0.57		0.72	0.62	0.24	0.83	0.98	0.98	0.87	0.92	-0.96	0.94	0.99	-0.12	0.93	0.98	0.88
Non Current Assets Total	0.88	0.51	0.17	0.22	0.9	0.56	0.8	-0.66	-0.17	0.68	0.72		0.03	0.72	0.63	0.84	0.75	0.63	0.9	-0.73	0.78	0.71	-0.71	0.9	0.83	0.35
Non Currrent Assets Other	0.45	0.58	0.97	0.96	0.43	0.65	0.57	-0.7	-0.97	0.12	0.62	0.03		-0.07	0.56	0.51	0.56	0.62	0.41	-0.7	0.64	0.67	0.43	0.43	0.52	0.7
Other Assets	0.48	-0.01	-0.08	-0.06	0.5	0.3	0.44	-0.21	0.08	0.33	0.24	0.72	-0.07		0.35	0.4	0.31	0.3	0.51	-0.41	0.49	0.3	-0.75	0.5	0.4	-0.18
Long Term Debt	0.79	0.88	0.65	0.68	0.78	0.99	0.85	-0.81	-0.67	0.54	0.83	0.63	0.56	0.35		0.81	0.82	0.98	0.77	-0.82	0.85	0.86	-0.05	0.78	0.81	0.76
Cash And Short Term Investments	0.99	0.81	0.66	0.69	0.99	0.8	0.98	-0.96	-0.66	0.61	0.98	0.84	0.51	0.4	0.81		0.97	0.86	0.99	-0.96	0.95	0.97	-0.32	0.99	1.0	0.77
Net Receivables	0.95	0.81	0.69	0.71	0.95	0.82	0.98	-0.96	-0.7	0.44	0.98	0.75	0.56	0.31	0.82	0.97		0.85	0.94	-0.94	0.91	0.96	-0.25	0.95	0.97	0.83
Common Stock Shares Outstanding	0.84	0.94	0.73	0.75	0.83	0.97	0.87	-0.87	-0.73	0.56	0.87	0.63	0.62	0.3	0.98	0.86	0.85		0.82	-0.87	0.87	0.89	-0.07	0.83	0.86	0.78
Short Term Investments	1.0	0.75	0.55	0.59	1.0	0.74	0.96	-0.91	-0.55	0.63	0.92	0.9	0.41	0.51	0.77	0.99	0.94	0.82		-0.93	0.92	0.91	-0.47	1.0	0.98	0.65
Non Current Liabilities Total	-0.95	-0.78	-0.79	-0.82	-0.94	-0.83	-0.98	0.97	0.79	-0.55	-0.96	-0.73	-0.7	-0.41	-0.82	-0.96	-0.94	-0.87	-0.93		-0.98	-0.98	0.2	-0.94	-0.96	-0.77
Other Current Assets	0.94	0.75	0.73	0.76	0.93	0.86	0.97	-0.93	-0.74	0.64	0.94	0.78	0.64	0.49	0.85	0.95	0.91	0.87	0.92	-0.98		0.97	-0.21	0.93	0.95	0.74
Other Stockholder Equity	0.94	0.84	0.79	0.82	0.93	0.87	0.98	-0.98	-0.8	0.59	0.99	0.71	0.67	0.3	0.86	0.97	0.96	0.89	0.91	-0.98	0.97		-0.09	0.93	0.97	0.87
Total Liab	-0.41	0.07	0.37	0.35	-0.45	0.03	-0.27	0.1	-0.39	-0.18	-0.12	-0.71	0.43	-0.75	-0.05	-0.32	-0.25	-0.07	-0.47	0.2	-0.21	-0.09		-0.45	-0.32	0.32
Net Invested Capital	1.0	0.76	0.57	0.61	1.0	0.76	0.96	-0.92	-0.57	0.63	0.93	0.9	0.43	0.5	0.78	0.99	0.95	0.83	1.0	-0.94	0.93	0.93	-0.45		0.99	0.67
Total Current Assets	0.99	0.81	0.66	0.69	0.99	0.8	0.98	-0.96	-0.66	0.62	0.98	0.83	0.52	0.4	0.81	1.0	0.97	0.86	0.98	-0.96	0.95	0.97	-0.32	0.99		0.77
Non Current Liabilities Other	0.69	0.87	0.83	0.84	0.67	0.79	0.78	-0.87	-0.84	0.38	0.88	0.35	0.7	-0.18	0.76	0.77	0.83	0.78	0.65	-0.77	0.74	0.87	0.32	0.67	0.77

Click cells to compare fundamentals

Athira Pharma Account Relationship Matchups

Athira Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.2M	279.6M	332.0M	258.2M	160.2M	190.1M
Short Long Term Debt Total	1.6M	1M	1.9M	1.9M	1.6M	1.6M
Other Current Liab	852K	3.0M	8.1M	18.3M	28.0M	29.4M
Total Current Liabilities	1.3M	4.4M	9.3M	21.4M	28.8M	30.3M
Total Stockholder Equity	(19.7M)	274.3M	321.1M	235.1M	130.2M	169.8M
Net Tangible Assets	(19.7M)	274.3M	321.1M	235.1M	270.4M	175.1M
Net Debt	(503K)	(59.6M)	(108.6M)	(94.1M)	(89.0M)	(93.4M)
Retained Earnings	(21.1M)	(41.0M)	(95.9M)	(191.5M)	(309.2M)	(293.7M)
Accounts Payable	421K	1.2M	567K	2.5M	129K	122.6K
Cash	2.1M	60.6M	110.5M	96.0M	90.6M	66.6M
Non Current Assets Total	29K	87.2M	71.2M	50.6M	5.5M	5.2M
Non Currrent Assets Other	29K	132K	56K	475K	1.1M	1.1M
Other Assets	29K	84.6M	5.3M	0.0	1.0	0.95
Cash And Short Term Investments	2.1M	184.7M	253.8M	200.3M	147.4M	145.4M
Net Receivables	7K	1.3M	2.3M	1.2M	1.6M	1.2M
Common Stock Shares Outstanding	32.6M	32.5M	36.9M	37.7M	38.0M	33.7M
Short Term Investments	0.0	124.1M	143.2M	104.4M	56.8M	78.8M
Liabilities And Stockholders Equity	2.2M	279.6M	332.0M	258.2M	160.2M	190.1M
Non Current Liabilities Total	20.6M	876K	1.6M	1.6M	1.2M	1.2M
Other Current Assets	97K	6.4M	4.7M	6.0M	5.7M	4.2M
Other Stockholder Equity	1.4M	315.3M	417.4M	428.6M	439.7M	294.0M
Total Liab	21.9M	5.3M	10.9M	23.0M	30.1M	20.4M
Net Invested Capital	(18.2M)	274.3M	321.1M	235.1M	130.2M	170.2M
Total Current Assets	2.2M	192.3M	260.8M	207.5M	154.7M	150.8M
Non Current Liabilities Other	1.0M	876K	1.6M	1.6M	1.8M	1.3M
Net Working Capital	887K	187.9M	251.5M	186.1M	125.9M	138.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:

How To Invest In Athira

Details

Is Athira Stock a good investment?

Details

What is Athira Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.84)

Return On Assets

(0.48)

Return On Equity

(0.85)

The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Athira Other Liab vs Net Debt Analysis

Other Liab vs Net Debt

Other Liab vs Net Debt Correlation Analysis

Correlation Coefficient

Other Liab

Net Debt

Athira Pharma fundamental ratios Correlations

Athira Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Athira Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Retained Earnings	- 1.0	Total Current Liabilities
Retained Earnings	- 1.0	Other Current Liab
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Non Current Liabilities Total
Other Current Assets	- 0.98	Non Current Liabilities Total
Other Stockholder Equity	- 0.98	Net Debt